.01
About
Sporos is transforming knowledge into new hope for patients with cancer and immune diseases. Harnessing our vast network, strategic resources, and operational expertise, the Sporos team of highly accomplished leaders identifies novel disease mechanisms and catalyzes the development of breakthrough medicines.
.02
Team
With a mix of impressive scientific expertise and operational understanding of the biotech industry, as well as deep roots in the burgeoning Houston biotech ecosystem, the Sporos leadership team is uniquely positioned to identify and advance a growing pipeline of first-in-class treatment options.
.03
Pipeline
We are advancing a pipeline of breakthrough therapies diversified across four entities with a focus on cancer and serious immune disease. Through our vast network of scientific experts, we aim to identify first-in-class therapeutic approaches with the potential for significant patient impact.
Clinical stage company focused on breakthrough medicines for cancer, inflammation, and fibrosis.
Development stage company focused on novel immune regulatory antibody therapeutics for cancer and autoimmune and infectious diseases.
Pioneering the discovery and development of novel small molecule inhibitors targeting cellular transporters at the nexus of tumor metabolism and immunity.
Development stage company focused on novel therapies targeting factors produced by cancer-associated fibroblasts, critical for tumor growth.
.04
Recent News
View the latest news and press releases from Sporos Bioventures
Sporos Bioventures Appoints Amit Rakhit, M.D. as Chief Executive Officer
HOUSTON, Texas., September 29, 2021 — Sporos Bioventures, LLC, a private biotechnology company catalyzing the rapid development of …
Tvardi Therapeutics Raises $74 Million in Series B Financing to Advance Clinical Programs
HOUSTON, Texas, June 23, 2021 — Tvardi Therapeutics, Inc. (“Tvardi”) a privately held, clinical-stage biopharmaceutical company focused on …
Stellanova Therapeutics, Inc. Announces Closing of $15.5 Million Series A Financing
Proceeds will support development of antibody drugs and discovery platform targeting pro-tumorigenic factors produced by fibroblasts in the …
Asylia Therapeutics, Inc. Announces Closing of $14.5 Million Series A Financing
Proceeds will support development of novel antibody drugs that convert immunologically “cold” tumors into treatable “hot” tumors, with …